ATE241992T1 - Verwendung von transduzierten myogenischen zellen zur schmerzhinderung und zur behandlung der verhaltungs- und wahrnehmungsbnormalitäten - Google Patents

Verwendung von transduzierten myogenischen zellen zur schmerzhinderung und zur behandlung der verhaltungs- und wahrnehmungsbnormalitäten

Info

Publication number: ATE241992T1
Authority: AT; Austria
Prior art keywords: myogenic cells; peptide; prevent pain; transduced; cells
Prior art date: 1997-08-11

Application number

AT98201068T

Other languages

English (en)

Inventor

Peter K Law

Original Assignee

Cell Therapy Res Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-11

Filing date

1998-04-07

Publication date

2003-06-15

1998-04-07 Application filed by Cell Therapy Res Foundation filed Critical Cell Therapy Res Foundation

2003-06-15 Application granted granted Critical

2003-06-15 Publication of ATE241992T1 publication Critical patent/ATE241992T1/de

Links

230000001114 myogenic effect Effects 0.000 title abstract 3
230000003542 behavioural effect Effects 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
102000003840 Opioid Receptors Human genes 0.000 abstract 1
108090000137 Opioid Receptors Proteins 0.000 abstract 1
102100024304 Protachykinin-1 Human genes 0.000 abstract 1
101800003906 Substance P Proteins 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000007774 longterm Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
230000002463 transducing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Rheumatology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Addiction (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

AT98201068T 1997-08-11 1998-04-07 Verwendung von transduzierten myogenischen zellen zur schmerzhinderung und zur behandlung der verhaltungs- und wahrnehmungsbnormalitäten ATE241992T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5519997P	1997-08-11	1997-08-11

Publications (1)

Publication Number	Publication Date
ATE241992T1 true ATE241992T1 (de)	2003-06-15

Family

ID=21996302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98201068T ATE241992T1 (de)	1997-08-11	1998-04-07	Verwendung von transduzierten myogenischen zellen zur schmerzhinderung und zur behandlung der verhaltungs- und wahrnehmungsbnormalitäten

Country Status (6)

Country	Link
US (1)	US7166279B2 (de)
EP (1)	EP0898967B1 (de)
JP (1)	JPH11147829A (de)
AT (1)	ATE241992T1 (de)
CA (1)	CA2225185A1 (de)
DE (1)	DE69815230T2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU770889B2 (en)	1999-07-23	2004-03-04	Genvec, Inc.	Muscle cells and their use in cardiac repair
JP2004520009A (ja) *	2000-08-08	2004-07-08	エム．ジー．ヴィ．エス．リミテッド	核酸構築物、それにより形質転換された血管細胞、血管形成を誘発するためのそれを用いた医薬組成物および方法
US7252819B2 (en) *	2001-11-08	2007-08-07	The Regents Of The University Of California	Methods and compositions for correction of cardiac conduction disturbances
JP4549609B2 (ja) *	2002-04-11	2010-09-22	エスエス製薬株式会社	被覆固形催眠製剤
US6932804B2 (en) *	2003-01-21	2005-08-23	The Regents Of The University Of California	System and method for forming a non-ablative cardiac conduction block
US20040106896A1 (en) *	2002-11-29	2004-06-03	The Regents Of The University Of California	System and method for forming a non-ablative cardiac conduction block
WO2003095016A1 (en) *	2002-05-08	2003-11-20	The Regents Of The University Of California	System and method for forming a non-ablative cardiac conduction block
US7317950B2 (en) *	2002-11-16	2008-01-08	The Regents Of The University Of California	Cardiac stimulation system with delivery of conductive agent
US20080167248A1 (en) *	2004-04-26	2008-07-10	Immuneregen Biosciences, Inc.	Anti-Aging Effects Of Substance P
US8889122B2 (en)	2005-05-09	2014-11-18	Mytogen, Inc.	Cellular cardiomyoplasty as supportive therapy in patients with heart disease
US20090017080A1 (en) *	2007-03-15	2009-01-15	Paul Robert Tanner	Personal care kit having skin care compositions with a readily perceptible difference
US8518001B2 (en) *	2007-06-13	2013-08-27	The Procter & Gamble Company	Skin treatment device
WO2009140367A1 (en) *	2008-05-15	2009-11-19	Wyeth	Method of delivering a skin benefit
US20100224205A1 (en) *	2008-12-09	2010-09-09	Shekhar Mitra	Device and methods for modifying keratinous surfaces
CA2749085A1 (en)	2009-01-16	2010-07-22	The Procter & Gamble Company	Apparatus and methods for modifying keratinous surfaces
US20150050300A1 (en)	2013-08-16	2015-02-19	Peter K. Law	Disease prevention and alleviation by human myoblast transplantation
JP6374991B2 (ja)	2014-06-13	2018-08-15	ザプロクターアンドギャンブルカンパニー	トリートメント組成物を角質表面に付着させるためのカートリッジ
US20160114349A1 (en)	2014-06-13	2016-04-28	The Procter & Gamble Company	Device and methods for depositing materials on hard surfaces
EP3154417A2 (de)	2014-06-13	2017-04-19	The Procter & Gamble Company	Vorrichtung und verfahren zur veränderung von keratinoberflächen
KR20170002615A (ko)	2014-06-13	2017-01-06	더 프록터 앤드 갬블 캄파니	각질 표면을 변경하는 처리 조성물, 장치 및 방법
US10156036B2 (en)	2014-06-13	2018-12-18	The Procter & Gamble Company	Device and methods for applying compositions to fabric surfaces
CA2949116C (en)	2014-06-13	2018-11-06	The Procter & Gamble Company	Apparatus and methods for modifying keratinous surfaces
US10518291B2 (en)	2014-06-13	2019-12-31	The Procter & Gamble Company	Device and methods for modifying surfaces
CN106456055B (zh)	2014-06-13	2020-04-14	宝洁公司	用于使角质表面改性的设备和方法
CN106457288B (zh)	2014-06-13	2021-05-11	宝洁公司	改变角质表面的设备和方法
US9955769B2 (en)	2014-07-25	2018-05-01	The Procter & Gamble Company	Applicator heads for handheld treatment apparatus for modifying keratinous surfaces
US10314378B2 (en)	2014-07-25	2019-06-11	The Procter & Gamble Company	Cartridge assembly for a dispensing device
US11083880B2 (en)	2014-07-25	2021-08-10	The Procter & Gamble Company	Angled cartridge assembly for a dispensing device
US9949552B2 (en)	2014-07-25	2018-04-24	The Procter & Gamble Company	Handheld treatment apparatus for modifying keratinous surfaces
US10188193B2 (en)	2014-07-25	2019-01-29	The Procter & Gamble Company	Applicator heads for handheld treatment apparatus for modifying keratinous surfaces
US11116302B2 (en)	2015-06-11	2021-09-14	The Procter & Gamble Company	Apparatus and methods for modifying keratinous surfaces
EP3307129B1 (de)	2015-06-11	2025-02-26	The Procter & Gamble Company	Vorrichtung und verfahren zum aufbringen von zusammensetzungen auf oberflächen
US9962532B2 (en)	2015-06-11	2018-05-08	The Procter & Gamble Company	Cartridges for use in an apparatus for modifying keratinous surfaces
US9949547B2 (en)	2015-06-11	2018-04-24	The Procter & Gamble Company	Cartridges for use in an apparatus for modifying keratinous surfaces
US10166799B2 (en)	2015-12-07	2019-01-01	The Procter & Gamble Company	Service stations for handheld fluid jet apparatuses
US9616668B1 (en)	2015-12-07	2017-04-11	The Procter & Gamble Company	Servicing cassettes for handheld fluid jet apparatuses for use in modifying surfaces
US10391042B2 (en)	2015-12-07	2019-08-27	The Procter & Gamble Company	Treatment compositions, apparatus and methods for modifying keratinous surfaces
US10945515B2 (en)	2017-06-16	2021-03-16	The Procter & Gamble Company	Personal care device with audible feedback
US11076675B2 (en)	2017-06-16	2021-08-03	The Procter & Gamble Company	Method for camouflaging tonal imperfections
US11090238B2 (en)	2017-06-16	2021-08-17	The Procter & Gamble Company	Array of cosmetic compositions for camouflaging tonal imperfections
WO2021089162A1 (en)	2019-11-07	2021-05-14	L'oreal	Microdermabrasion device for coloring the skin
EP4440378A1 (de)	2021-12-03	2024-10-09	The Procter & Gamble Company	Körperpflegevorrichtung mit hörbarem feedback

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE77033B1 (en) *	1989-08-16	1997-11-19	Univ Tulane	Substance P antagonists
WO1992016547A1 (en) *	1991-03-15	1992-10-01	The Children's Medical Center Corporation	Controlling nk-1 receptor-mediated responses and related diagnostics
EP1407788A2 (de) *	1994-12-13	2004-04-14	Peter K. Law	Myoblast-Therapie für Säugetierkrankheiten

1998
- 1998-03-06 CA CA002225185A patent/CA2225185A1/en not_active Abandoned
- 1998-04-07 EP EP98201068A patent/EP0898967B1/de not_active Expired - Lifetime
- 1998-04-07 AT AT98201068T patent/ATE241992T1/de not_active IP Right Cessation
- 1998-04-07 DE DE69815230T patent/DE69815230T2/de not_active Expired - Lifetime
- 1998-08-11 JP JP10227422A patent/JPH11147829A/ja active Pending
2001
- 2001-11-08 US US09/986,344 patent/US7166279B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69815230D1 (de)	2003-07-10
JPH11147829A (ja)	1999-06-02
EP0898967B1 (de)	2003-06-04
DE69815230T2 (de)	2004-05-06
CA2225185A1 (en)	1999-02-11
EP0898967A1 (de)	1999-03-03
US7166279B2 (en)	2007-01-23
US20020044925A1 (en)	2002-04-18
HK1016897A1 (en)	1999-11-12

Legal Events

Date	Code	Title	Description
2003-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69815230D1 (de)	2003-07-10	Verwendung von transduzierten myogenischen Zellen zur Schmerzhinderung und zur Behandlung der Verhaltungs- und Wahrnehmungsbnormalitäten
Liem et al.	2004	Anesthetic requirement is increased in redheads
Kumazawa et al.	1977	Primate cutaneous sensory units with unmyelinated (C) afferent fibers
Shalev et al.	2001	Leptin attenuates acute food deprivation-induced relapse to heroin seeking
Fields	2004	State-dependent opioid control of pain
Durand et al.	2002	Current-induced vasodilation during water iontophoresis (5 min, 0.10 mA) is delayed from current onset and involves aspirin sensitive mechanisms
RU2000130209A (ru)	2002-10-20	Новое применение
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69604509D1 (de)	1999-11-04	Vorrichtung zur verabreichung von medikamenten und genen durch elektroporation
ATE298230T1 (de)	2005-07-15	Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress
DE69839815D1 (de)	2008-09-11	Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE179339T1 (de)	1999-05-15	Elektrische stimulierung zur behandlung von inkontinenz und anderen neuromuskularerkrankungen
ES2161246T3 (es)	2001-12-01	Factor transformante de crecimiento alfa h1.
NZ319646A (en)	2000-08-25	Use of a rar-y-specific agonist ligand for increasing the rate of apoptosis
NZ514091A (en)	2004-01-30	Vascular adhesion molecules and modulation of their function
DE69512760D1 (de)	1999-11-18	Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
Shoham et al.	2025	Open label randomized controlled trial of the efficacy and safety of NexoBrid compared to standard of care in children with burns
Talagas et al.	2018	Intraepidermal nerve fibres are not the exclusive tranducers of nociception
DE69822276D1 (de)	2004-04-15	Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
Peplow et al.	2014	Repeated application of electroacupuncture ameliorates hyperglycemia in obese Zucker diabetic fatty rats
DE69728654D1 (de)	2004-05-19	Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
Yang et al.	2001	Effects of microinjection of OFQ into PAG on spinal dorsal horn WDR neurons in rats
Milne et al.	2001	The release of spinal prostaglandin E2 and the effect of nitric oxide synthetase inhibition during strychnine-induced allodynia
Takita et al.	2003	Roles of nociceptin/orphanin FQ and nociceptin/orphanin FQ peptide receptor in respiratory rhythm generation in the medulla oblongata: an in vitro study
Nihonmatsu	2023	Somatosensory Stimulation (Acupuncture) Modulates Spinal and Supraspinal Motor Neuron Excitability